Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $669.3 million.

  • Nurix Therapeutics' Liabilities and Shareholders Equity rose 1.73% to $522.5 million in Q3 2025 from the same period last year, while for Aug 2025 it was $2.4 billion, marking a year-over-year increase of 41.67%. This contributed to the annual value of $669.3 million for FY2024, which is 88.23% up from last year.
  • Per Nurix Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $669.3 million for FY2024, which was up 88.23% from $355.6 million recorded in FY2023.
  • Nurix Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $669.3 million during FY2024, with a 5-year trough of $355.6 million in FY2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $416.8 million (2022), whereas its average is $480.6 million.
  • Per our database at Business Quant, Nurix Therapeutics' Liabilities and Shareholders Equity skyrocketed by 799.80% in 2020 and then decreased by 14.68% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $396.3 million in 2020, then rose by 20.29% to $476.8 million in 2021, then decreased by 12.59% to $416.8 million in 2022, then declined by 14.68% to $355.6 million in 2023, then skyrocketed by 88.23% to $669.3 million in 2024.